Contraceptives

Biosyn announces positive results for trials of microbicide gel

Published in Women's Health Weekly, June 13th, 2002

Biosyn, Inc. announced at the Microbicides 2002 Conference in Antwerp, Belgium, successful results of two clinical studies for Savvy (C31G intravaginal gel), currently in development as a contraceptive and for the prevention of sexually transmitted diseases (STDs).

Presented were results of a phase I/II dose escalation study in which 64 women used Savvy gel in single and multiple doses for 2 weeks. Data from the trial indicated that Savvy met the primary endpoints of safety and acceptability.

Results of the second trial, a phase I/II postcoital testing (PCT) study investigating the safety and spermicidal efficacy of three different concentrations of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-06-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry